Remo Panaccione, MD: Risankizumab Maintenance Therapy Efficacy, Dosing for Ulcerative Colitis
Panaccione provides insight into the efficacy of risankizumab maintenance therapy by induction outcomes and explains which dose may be more effective.
Violeta Popov, MD, PhD: Do GLP-1 RAs Need to Be Held Before Endoscopy?
Popov reviews findings from her late-breaking presentation at ACG 2024 suggesting GLP-1 RAs may not need to be held prior to upper endoscopy.
Satish Rao, MD, PhD: Biofeedback Versus Dextranomer Hyaluronate for Fecal Incontinence
Rao explains the comparative effectiveness of biofeedback and dextranomer injections for treating fecal incontinence.
Kishore Iyer, MBBS, MSc: STARS Subgroup Analyses for Apraglutide in SBS-IF
Iyer reviews findings from subgroup analyses of the phase 3 STARS study of apraglutide for SBS-IF based on demographics and disease characteristics.
Evan Dellon, MD, MPH: “Promising” Phase 3 Cendakimab Data for Eosinophilic Esophagitis
Dellon reviews phase 3 data supporting the 48-week safety and efficacy of cendakimab for treating EoE.
Marlyn Mayo, MD: Elafibranor’s Safety, Efficacy in Patients with Advanced PBC
Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.
Kishore Iyer, MBBS, MSc: Defining Short Bowel Syndrome, What Apraglutide Could Offer
Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.
Bruce Sands, MD: Long-Term Data for Mirikizumab in Ulcerative Colitis, Crohn’s Disease
Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.
Jordan Axelrad, MD, MPH: Addressing Nonadherence to IBD Therapies with Remote Monitoring
Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.
Second-Line Obeticholic Acid for PBC Used Infrequently and with Delays
Data from ACG 2024 show only 1 in 12 patients eligible for second-line PBC therapy are actually doing receiving it—and it may take up to a year to initiate.
Hormone Replacement Therapy Linked to Greater IBS, Gastric Motility Disorder Risk
Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.
ChatGPT Reliable for Gastrointestinal Disease-Based Diet Advice
ChatGPT may provide helpful information around gastroparesis, IBS and celiac disease diets, according to findings from a new study.
GLP-1 RAs Increase Residual Gastric Content But Pose Low Medical Risk During Endoscopy
Braden Kuo, MD, explains how GLP-1 RA use increases residual gastric content but does not significantly impact negative endoscopy outcomes.
Brian Lacy, MD, PhD: Profiling Gastric Activity Variations with Multiday Testing
Lacy explains the potential value of an ambulatory wireless patch test for identifying unique gastric activity patterns and individualizing patient care.
Ronnie Fass, MD: On-Demand Vonoprazan for Non-Erosive GERD “Within Our Reach”
Fass reviews findings from a post hoc analysis of a phase 2 trial suggesting the value of vonoprazan as an on-demand NERD treatment.
Basile Njei, MD, MPH, PhD: Increasing Lean MASLD Awareness, Improving Screening
Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.
Vitamin D Deficiency Linked to Worse IBD Hospital Outcomes
New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.
Timothy Ritter, MD: Real-World Data Supporting Fecal Microbiota for Recurrent C Diff
Ritter reviews findings from 2 real-world studies supporting the safety and efficacy of live-jslm (Rebyota) for recurrent C Diff infection.
AIMS65 Could Predict Treated Gastrointestinal Bleed Death, Rebleed Risks
New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.
Zegocractin Significantly Improves Acute Pancreatitis Symptoms in Phase 2 CARPO
The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.
Infliximab Improves Ulcerative Colitis, Crohn's Disease Regardless of Immunosuppressants
Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.
Brian Lacy, MD, PhD: Rethinking Motility Testing with a Noninvasive Wireless Patch System
Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.
Clinical Quiz: ACG Alcohol-Associated Liver Disease Guideline
Test your knowledge of the 2024 American College of Gastroenterology alcohol-associated liver disease guidelines with this clinical quiz!
Clinical Quiz: ACG Guidelines on Acute Pancreatitis Management
Test your knowledge of the 2024 American College of Gastroenterology acute pancreatitis diagnosis and management guidelines with this clinical quiz!
Clinical Quiz: Diagnosing, Managing Common Focal Liver Lesions
Test your knowledge of the 2024 American College of Gastroenterology focal liver lesion diagnosis and management guidelines with this clinical quiz!
Clinical Quiz: ACG Guidelines for Treating Helicobacter Pylori Infection
Test your knowledge of the 2024 American College of Gastroenterology H. pylori management guidelines with this clinical quiz!
Positive Phase 2 Data for Omilancor in Crohn Disease, Ulcerative Colitis Presented at ACG
Results from both phase 2 trials were presented in poster abstracts at ACG 2023.
Andreas Kremer, MD, PhD, MHBA: Seladelpar for the Treatment of PBC
Kremer discusses new ad hoc findings from the phase 3 ENHANCE trial showing seladelpar's unique effect on pruritus in patients with PBC.
PRA023 Decreases Bowel Urgency, Movement in Patients with Ulcerative Colitis
Findings were presented in an abstract at ACG 2023, highlighting the importance of addressing bowel urgency in patients with ulcerative colitis.
Etrasimod Significantly Benefits Ulcerative Colitis Regardless of Corticosteroids
New data from ACG 2023 shows etrasimod-treated patients were able to achieve UC remission, with or without concomitant steroid treatment at baseline.
